Protein tyrosine kinase activity in breast cancer and its relation to prognostic indicators

Anticancer Research

Volumn 16, Issue 5 B, 1996, Pages 3037-3041

  Kopreski, Michael S ^a   Witters, Lois ^b   Brennan Jr , William A ^b   Buckwalter, Elizabeth A ^b   Chinchilli, Vernon M ^b   Demers, Laurence M ^b   Lipton, Allan ^b,c  

^a SAIC FREDERICK INC   (United States)

^b PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^c PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Breast cancer; Epidermal growth factor; HER 2 neu; Prognostic indicators; Protein tyrosine kinase

Indexed keywords

ANTIBODY; PHOSPHOPROTEIN; PHOSPHOTYROSINE; PROTEIN TYROSINE KINASE;

ARTICLE; BREAST; BREAST CANCER; CANCER INVASION; CONTROLLED STUDY; DOT HYBRIDIZATION; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; METASTASIS; PRIORITY JOURNAL; PROGNOSIS;

BREAST; BREAST NEOPLASMS; FEMALE; HUMANS; NEOPLASM PROTEINS; PROGNOSIS; PROTEIN-TYROSINE KINASES;

EID: 0029827724     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Seshadri R, Firgaira FA, Horsfall DJ, McCaul K, Setlur V, and Kitchen P: Clinical significance of Her-2/neu oncogene amplification in primary breast cancer. J Clin Oncol 11: 1936-1942, 1993.
2. Tandon AK, Clark GM, Chamness GC, Ullrich A, and McGuire WL: Her-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol 7: 1120-1128, 1989.
3. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, and Press MF: Studies of the Her-2/neu protooncogene in human breast and ovarian cancer. Science 244: 707-712, 1989.
4. Allred DC, Clark GM, Tandon AK, Molina R, Tormey DC, Osborne CK, Gilchrist KW, Mansour EG, Abeloff M, Eudey L, and McGuire WL: Her-2/neu in node-negative breast cancer: Prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol 10: 599-605, 1992.
5. Paterson MC, Dietrich KD, Danyluk J, Paterson AHG, Lees AW, Jamil N, Hanson J, Jenkins H, Krause BE, McBlain WA, Slamon DJ, and Fourney RM: Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer. Cancer Res 51: 556-567, 1991.
6. Sainsbury JRC, Farndon JR, Sherbet GV, and Harris AL: Epidermal-growth factor receptors and oestrogen receptors in human breast cancer. Lancet 1: 364-366, 1985.
7. Gusterson BA, Gelber RD, Goldhirsch A, Price KN, Save-Soderborgh J, Anbazhagan R, Styles J, Rudenstam C-M, Golouh R, Reed R, Martinez-Tello F, Tiltman A, Torhorst J, Grigolato P, Bettelheim R, Neville AM, Burki K, Castiglione M, Collins J, Lindtner J, and Senn H-J: Prognostic importance of c-erbB-2 expression in breast cancer. J Clin Oncol 10: 1049-1056, 1992.
8. Wright C, Nicholson S, Angus B, Sainsbury JRC, Farndon J, Cairns J, Harris AL, and Home CHW: Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer 65:118-121, 1992.
9. Hennipman A, van Oirschot BA, Smits J, Rijksen G, and Staal GEJ: Tyrosine kinase activity in breast cancer, benign breast disease, and normal breast tissue. Cancer Res 49: 516-521, 1989.
10. Ottenhoff-Kalff AE, Rijksen G, van Beurden EACM, Hennipman A, Michels AA, and Staal GEJ: Characterization of protein tyrosine kinases from human breast cancer: Involvement of the c-src oncogene product. Cancer Res 52: 4773-4778, 1992.
11. Bolla M, Rostaing-Puissant B, Chedin M, Souvignet C, Marron-Charriere J, Colonna M, Berland E, and Chambaz EM: Protein tyrosine kinase activity as a prognostic parameter in breast cancer, a pilot study. Breast Cancer Res Treat 26: 283-287, 1993.
12. Romain S, Chinot O, Klijn JGM, van Putten WLJ, Guirou O, Look M, Martin PM, and Foekens JA: Prognostic value of cytosolic tyrosine kinase activity in 249 node-positive breast cancer patients. Br J Cancer 70: 304-308, 1994.
13. Lower EE, Franco RS, Miller MA, and Martelo OJ: Enzymatic and immunohistochemical evaluation of tyrosine phosphorylation in breast cancer specimens. Breast Cancer Res Treat 26: 217-224, 1993.
14. Rijksen G, van Oirschot BA, and Staal GEJ: A nonradioactive dotblot assay for protein tyrosine kinase activity. Anal Biochem 182: 98-102, 1989.
15. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254, 1976.
16. Braun S, Raymond WE, and Racker E: Synthetic tyrosine polymers as substrates and inhibitors of tyrosine-specific protein kinases. J Biol Chem 259: 2051-2054, 1984.
17. Durocher Y, and Chevalier S: Protein tyrosine kinases in human breast cancer: kinetic properties and evidence for the presence of two forms of native enzyme. Breast Cancer Res Treat 17: 99-107, 1990.
18. Chen L-c, Kurisu W, Ljung B-M, Goldman ES, Moore II D, and Smith HS: Heterogeneity for allelic loss in human breast cancer. J Natl Cancer Inst 84: 506-510, 1992.
19. Sakr WA, Macoska JA, Benson P, Grignon DJ, Wolman SR, Pontes JE, and Crissman JD: Allelic loss in locally metastatic, multisampled prostate cancer. Cancer Res 54: 3273-3277, 1994.
20. Nagel S, Borisch B, Thein SL, Oestreicher M, Nothiger F, Birrer S, Tobler A, and Fey MF: Somatic mutations detected by mini- and microsatellite DNA markers reveal clonal intratumor heterogeneity in gastrointestinal cancers. Cancer Res 55: 2866-2870, 1995.
21. Albino AP, Lloyd KO, Houghton AN, Oettgen HF, and Old LJ: Heterogeneity in surface antigen and glycoprotein expression of cell lines derived from different melanoma metastases of the same patient. Implications for the study of tumor antigens. J Exp Med 154: 1764-1778, 1981.
22. Brennan MJ, Donegan WL, and Appleby DE: The variability of estrogen receptors in metastatic breast cancer. Am J Surg 137: 260-262, 1979.
23. Niehans GA, Singleton TP, Dykoski D, and Kiang DT: Stability of HER2/neu expression over time and at multiple metastatic sites. J Natl Cancer Inst 85: 1230-1235, 1993.
24. Lacroix H, Iglehart JD, Skinner MA, and Kraus MH: Overexpression of erbB-2 or EGF receptor proteins present in early stage mammary carcinoma is detected simultaneously in matched primary tumors and regional metastases. Oncogene 4: 145-151, 1989.
25. Ciocca DR, Fujimura FK, Tandon AK, Clark GM, Mark C, Lee-Chen G-J, Pounds GW, Vendely P, Owens MA, Pandian MR, and McGuire WL: Correlation of HER-2/neu amplification with expression and with other prognostic factors in 1103 breast cancers. J Natl Cancer Inst 84: 1279-1282, 1992.
26. Schonborn I, Zschiesche W, Spitzer E, Minguillon C, Mohner M, Ebeling K, and Grosse R: C-erbB-2 overexpression in primary breast cancer: independent prognostic factor in patients at high risk. Breast Cancer Res Treat 29: 287-295, 1994.
27. Gramlich TL, Cohen C, Fritsch C, DeRose PB, and Gansler T: Evaluation of c-erbB-2 amplification in breast carcinoma by differential polymerase chain reaction. Am J Clin Pathol 101: 493-499, 1994.
28. Pierce LJ, Merino MJ, D'Angelo T, Barker EA, Gilbert L, Cowan KH, Steinberg SM, and Glatstein E: Is c-erb B-2 a predictor for recurrent disease in early stage breast cancer? Int J Radiat Oncol Biol Phys 28: 395-403, 1994.
29. Horiguchi J, Iiano Y, Takei H, Yokoe T, Ishida T, and Morishita Y: Immunohistochemical study on the expression of c-erbB-2 oncoprotein in breast cancer. Oncology 51: 47-51, 1994.
30. Nagai MA, Marques LA, Torloni H, and Brentani MM: Genetic alterations in c-erbB-2 protooncogene as prognostic markers in human primary breast tumors. Oncology 50: 412-417, 1993.
31. Klijn JGM, Berns PMJJ, Schmitz PIM, and Foekens JA: The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: A review on 5232 patients. Endocrine Rev 13: 3-17, 1992.
32. Kidd KR, Kerns B-JM, Dodge RK, and Wiener JR: Histochemical staining of protein-tyrosine phosphatase activity in primary human mammary carcinoma: relationship with established prognostic indicators. J Histochem Cytochem 40: 729-735, 1992.
33. Partanen S: Phosphotyrosyl-proteins in human breast cancer. Anticancer Res 13: 1777-1780, 1993.